Literature DB >> 27694664

HTA - Algorithm or Process? Comment on "Expanded HTA: Enhancing Fairness and Legitimacy".

Anthony J Culyer1.   

Abstract

Daniels, Porteny and Urrutia et al make a good case for the idea that that public decisions ought to be made not only "in the light of" evidence but also "on the basis of" budget impact, financial protection and equity. Health technology assessment (HTA) should, they say, be accordingly expanded to consider matters additional to safety and cost-effectiveness. They also complain that most HTA reports fail to develop ethical arguments and generally do not even mention ethical issues. This comment argues that some of these defects are more apparent than real and are not inherent in HTA - as distinct from being common characteristics found in poorly conducted HTAs. More generally, HTA does not need "extension" since (1) ethical issues are already embedded in HTA processes, not least in their scoping phases, and (2) HTA processes are already sufficiently flexible to accommodate evidence about a wide range of factors, and will not need fundamental change in order to accommodate the new forms of decision-relevant evidence about distributional impact and financial protection that are now starting to emerge. HTA and related techniques are there to support decision-makers who have authority to make decisions. Analysts like us are there to support and advise them (and not to assume the responsibilities for which they, and not we, are accountable). The required quality in HTA then becomes its effectiveness as a means of addressing the issues of concern to decision-makers. What is also required is adherence by competent analysts to a standard template of good analytical practice. The competencies include not merely those of the usual disciplines (particularly biostatistics, cognitive psychology, health economics, epidemiology, and ethics) but also the imaginative and interpersonal skills for exploring the "real" question behind the decision-maker's brief (actual or postulated) and eliciting the social values that necessarily pervade the entire analysis. The product of such exploration defines the authoritative scope of an HTA.
© 2016 by Kerman University of Medical Sciences.

Entities:  

Keywords:  Deliberation; Economic Evaluation; Equity; Extended Cost-Effectiveness; HTA Processes; Quality-Adjusted Life-Year (QALY) Algorithm; Reference Case

Mesh:

Year:  2016        PMID: 27694664      PMCID: PMC4968254          DOI: 10.15171/ijhpm.2016.59

Source DB:  PubMed          Journal:  Int J Health Policy Manag        ISSN: 2322-5939


  16 in total

1.  The development of health technology assessment.

Authors:  David Banta
Journal:  Health Policy       Date:  2003-02       Impact factor: 2.980

2.  An equity framework for health technology assessments.

Authors:  Anthony J Culyer; Yvonne Bombard
Journal:  Med Decis Making       Date:  2011-11-07       Impact factor: 2.583

3.  Expanded HTA: Enhancing Fairness and Legitimacy.

Authors:  Norman Daniels; Thalia Porteny; Julian Urritia
Journal:  Int J Health Policy Manag       Date:  2015-11-06

4.  Toward a procedure for integrating moral issues in health technology assessment.

Authors:  Bjørn Hofmann
Journal:  Int J Technol Assess Health Care       Date:  2005       Impact factor: 2.188

5.  The bogus conflict between efficiency and vertical equity.

Authors:  Anthony J Culyer
Journal:  Health Econ       Date:  2006-11       Impact factor: 3.046

6.  Explicit incorporation of equity considerations into economic evaluation of public health interventions.

Authors:  Richard Cookson; Mike Drummond; Helen Weatherly
Journal:  Health Econ Policy Law       Date:  2009-02-16

7.  Why ethics should be part of health technology assessment.

Authors:  Bjørn Morten Hofmann
Journal:  Int J Technol Assess Health Care       Date:  2008       Impact factor: 2.188

8.  The ethics of accountability in managed care reform.

Authors:  N Daniels; J Sabin
Journal:  Health Aff (Millwood)       Date:  1998 Sep-Oct       Impact factor: 6.301

9.  Distributional cost-effectiveness analysis of health care programmes--a methodological case study of the UK Bowel Cancer Screening Programme.

Authors:  Miqdad Asaria; Susan Griffin; Richard Cookson; Sophie Whyte; Paul Tappenden
Journal:  Health Econ       Date:  2014-05-02       Impact factor: 3.046

10.  Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis.

Authors:  Ole F Norheim; Rob Baltussen; Mira Johri; Dan Chisholm; Erik Nord; DanW Brock; Per Carlsson; Richard Cookson; Norman Daniels; Marion Danis; Marc Fleurbaey; Kjell A Johansson; Lydia Kapiriri; Peter Littlejohns; Thomas Mbeeli; Krishna D Rao; Tessa Tan-Torres Edejer; Dan Wikler
Journal:  Cost Eff Resour Alloc       Date:  2014-08-29
View more
  8 in total

1.  Deliberative Processes by Health Technology Assessment Agencies: A Reflection on Legitimacy, Values and Patient and Public Involvement Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".

Authors:  Mireille Goetghebeur; Marjo Cellier
Journal:  Int J Health Policy Manag       Date:  2021-03-14

2.  Using Cost-Effectiveness Analysis to Address Health Equity Concerns.

Authors:  Richard Cookson; Andrew J Mirelman; Susan Griffin; Miqdad Asaria; Bryony Dawkins; Ole Frithjof Norheim; Stéphane Verguet; Anthony J Culyer
Journal:  Value Health       Date:  2017-02       Impact factor: 5.725

3.  Ethics in HTA: Examining the "Need for Expansion".

Authors:  Payam Abrishami; Wija Oortwijn; Bjørn Hofmann
Journal:  Int J Health Policy Manag       Date:  2017-10-01

4.  Caring for Carers: Positive and Normative Challenges for Future Research on Carer Spillover Effects in Economic Evaluation.

Authors:  Padraig Dixon; Jeff Round
Journal:  Value Health       Date:  2019-05       Impact factor: 5.725

5.  Moving Towards Accountability for Reasonableness - A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study.

Authors:  Monika Wagner; Dima Samaha; Roman Casciano; Matthew Brougham; Payam Abrishami; Charles Petrie; Bernard Avouac; Lorenzo Mantovani; Antonio Sarría-Santamera; Paul Kind; Michael Schlander; Michele Tringali
Journal:  Int J Health Policy Manag       Date:  2019-07-01

6.  Expanding HTA - Correcting a Misattribution, Clarifying the Scope of HTA and CEA Comment on "Ethics in HTA: Examining the 'Need for Expansion'".

Authors:  Anthony J Culyer
Journal:  Int J Health Policy Manag       Date:  2019-12-01

Review 7.  Can reflective multicriteria be the new paradigm for healthcare decision-making? The EVIDEM journey.

Authors:  Mireille M Goetghebeur; Marjo S Cellier
Journal:  Cost Eff Resour Alloc       Date:  2018-11-09

8.  The Place and Importance of Patients in Deliberative Processes.

Authors:  Marjo S Cellier
Journal:  Front Med Technol       Date:  2021-11-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.